nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—lung cancer—colon cancer	0.45	1	CtDrD
Gefitinib—EGFR—colon cancer	0.196	0.767	CbGaD
Gefitinib—ABCB1—colon cancer	0.0595	0.233	CbGaD
Gefitinib—ABCG2—Irinotecan—colon cancer	0.0179	0.12	CbGbCtD
Gefitinib—ABCG2—Fluorouracil—colon cancer	0.0172	0.115	CbGbCtD
Gefitinib—ABCG2—Vincristine—colon cancer	0.0156	0.105	CbGbCtD
Gefitinib—ALB—Irinotecan—colon cancer	0.0123	0.0826	CbGbCtD
Gefitinib—ALB—Fluorouracil—colon cancer	0.0118	0.0793	CbGbCtD
Gefitinib—CYP2C9—Capecitabine—colon cancer	0.0108	0.0721	CbGbCtD
Gefitinib—CYP3A5—Irinotecan—colon cancer	0.00992	0.0664	CbGbCtD
Gefitinib—ABCG2—Methotrexate—colon cancer	0.00947	0.0634	CbGbCtD
Gefitinib—CYP3A5—Vincristine—colon cancer	0.00867	0.058	CbGbCtD
Gefitinib—ALB—Methotrexate—colon cancer	0.00653	0.0437	CbGbCtD
Gefitinib—ABCB1—Irinotecan—colon cancer	0.00645	0.0432	CbGbCtD
Gefitinib—CYP2C9—Fluorouracil—colon cancer	0.00638	0.0427	CbGbCtD
Gefitinib—ABCB1—Vincristine—colon cancer	0.00564	0.0378	CbGbCtD
Gefitinib—CYP3A4—Irinotecan—colon cancer	0.00387	0.0259	CbGbCtD
Gefitinib—ABCB1—Methotrexate—colon cancer	0.00342	0.0229	CbGbCtD
Gefitinib—CYP3A4—Vincristine—colon cancer	0.00338	0.0226	CbGbCtD
Gefitinib—ORM1—bile—colon cancer	0.00245	0.0812	CbGeAlD
Gefitinib—ERBB3—embryo—colon cancer	0.000769	0.0255	CbGeAlD
Gefitinib—CHEK2—bone marrow—colon cancer	0.00072	0.0239	CbGeAlD
Gefitinib—CHEK2—vagina—colon cancer	0.000689	0.0228	CbGeAlD
Gefitinib—ORM1—gall bladder—colon cancer	0.00068	0.0225	CbGeAlD
Gefitinib—CHEK2—Vindesine—Vincristine—colon cancer	0.00067	0.369	CbGdCrCtD
Gefitinib—Lapatinib—EGFR—colon cancer	0.00066	0.202	CrCbGaD
Gefitinib—ERBB3—epithelium—colon cancer	0.000628	0.0208	CbGeAlD
Gefitinib—MKNK2—epithelium—colon cancer	0.000597	0.0198	CbGeAlD
Gefitinib—ALB—gall bladder—colon cancer	0.000597	0.0198	CbGeAlD
Gefitinib—ERBB3—renal system—colon cancer	0.000582	0.0193	CbGeAlD
Gefitinib—MKNK2—smooth muscle tissue—colon cancer	0.000575	0.0191	CbGeAlD
Gefitinib—IRAK1—smooth muscle tissue—colon cancer	0.000575	0.0191	CbGeAlD
Gefitinib—MKNK2—renal system—colon cancer	0.000554	0.0183	CbGeAlD
Gefitinib—SBK1—lymph node—colon cancer	0.000512	0.017	CbGeAlD
Gefitinib—CSNK1E—digestive system—colon cancer	0.000495	0.0164	CbGeAlD
Gefitinib—IRAK4—lymphoid tissue—colon cancer	0.000493	0.0163	CbGeAlD
Gefitinib—ERBB3—lymphoid tissue—colon cancer	0.000484	0.016	CbGeAlD
Gefitinib—ERBB3—digestive system—colon cancer	0.000478	0.0158	CbGeAlD
Gefitinib—Afatinib—EGFR—colon cancer	0.000468	0.143	CrCbGaD
Gefitinib—MKNK2—lymphoid tissue—colon cancer	0.00046	0.0152	CbGeAlD
Gefitinib—MKNK2—digestive system—colon cancer	0.000454	0.0151	CbGeAlD
Gefitinib—MKNK1—lymphoid tissue—colon cancer	0.000454	0.015	CbGeAlD
Gefitinib—STK10—renal system—colon cancer	0.00045	0.0149	CbGeAlD
Gefitinib—IRAK4—bone marrow—colon cancer	0.000449	0.0149	CbGeAlD
Gefitinib—MKNK1—digestive system—colon cancer	0.000448	0.0149	CbGeAlD
Gefitinib—CHEK2—lymph node—colon cancer	0.000446	0.0148	CbGeAlD
Gefitinib—CSNK1E—vagina—colon cancer	0.000437	0.0145	CbGeAlD
Gefitinib—ERBB3—Vinblastine—Vincristine—colon cancer	0.00043	0.237	CbGdCrCtD
Gefitinib—IRAK4—vagina—colon cancer	0.00043	0.0143	CbGeAlD
Gefitinib—CHEK2—Vinorelbine—Vincristine—colon cancer	0.000423	0.233	CbGdCrCtD
Gefitinib—MKNK2—bone marrow—colon cancer	0.000419	0.0139	CbGeAlD
Gefitinib—IRAK1—bone marrow—colon cancer	0.000419	0.0139	CbGeAlD
Gefitinib—MKNK1—bone marrow—colon cancer	0.000413	0.0137	CbGeAlD
Gefitinib—MKNK2—vagina—colon cancer	0.000401	0.0133	CbGeAlD
Gefitinib—MKNK1—vagina—colon cancer	0.000396	0.0131	CbGeAlD
Gefitinib—EGFR—liver—colon cancer	0.000383	0.0127	CbGeAlD
Gefitinib—STK10—lymphoid tissue—colon cancer	0.000374	0.0124	CbGeAlD
Gefitinib—STK10—digestive system—colon cancer	0.000369	0.0122	CbGeAlD
Gefitinib—CSNK1E—liver—colon cancer	0.000369	0.0122	CbGeAlD
Gefitinib—IRAK4—liver—colon cancer	0.000363	0.012	CbGeAlD
Gefitinib—ERBB3—liver—colon cancer	0.000356	0.0118	CbGeAlD
Gefitinib—Appetite absent—Methotrexate—colon cancer	0.000344	0.00674	CcSEcCtD
Gefitinib—STK10—bone marrow—colon cancer	0.00034	0.0113	CbGeAlD
Gefitinib—MKNK2—liver—colon cancer	0.000338	0.0112	CbGeAlD
Gefitinib—IRAK1—liver—colon cancer	0.000338	0.0112	CbGeAlD
Gefitinib—MKNK1—liver—colon cancer	0.000334	0.0111	CbGeAlD
Gefitinib—Erlotinib—EGFR—colon cancer	0.000331	0.101	CrCbGaD
Gefitinib—STK10—vagina—colon cancer	0.000326	0.0108	CbGeAlD
Gefitinib—Vandetanib—SRC—colon cancer	0.000324	0.0991	CrCbGaD
Gefitinib—Mouth ulceration—Vincristine—colon cancer	0.000319	0.00625	CcSEcCtD
Gefitinib—Haemoptysis—Capecitabine—colon cancer	0.00031	0.00609	CcSEcCtD
Gefitinib—Bosutinib—SRC—colon cancer	0.000303	0.0927	CrCbGaD
Gefitinib—Pleural effusion—Capecitabine—colon cancer	0.0003	0.00588	CcSEcCtD
Gefitinib—EGFR—lymph node—colon cancer	0.000294	0.00974	CbGeAlD
Gefitinib—MAP2K5—vagina—colon cancer	0.000291	0.00965	CbGeAlD
Gefitinib—CHEK2—Vinblastine—Vincristine—colon cancer	0.000291	0.16	CbGdCrCtD
Gefitinib—Thrombophlebitis—Irinotecan—colon cancer	0.000288	0.00565	CcSEcCtD
Gefitinib—Hepatic failure—Vincristine—colon cancer	0.000285	0.00558	CcSEcCtD
Gefitinib—Febrile neutropenia—Methotrexate—colon cancer	0.000284	0.00558	CcSEcCtD
Gefitinib—CSNK1E—lymph node—colon cancer	0.000283	0.00937	CbGeAlD
Gefitinib—IRAK4—lymph node—colon cancer	0.000278	0.00922	CbGeAlD
Gefitinib—Eruption—Methotrexate—colon cancer	0.000278	0.00545	CcSEcCtD
Gefitinib—Thrombophlebitis—Fluorouracil—colon cancer	0.000276	0.00541	CcSEcCtD
Gefitinib—STK10—liver—colon cancer	0.000275	0.00912	CbGeAlD
Gefitinib—ERBB3—lymph node—colon cancer	0.000273	0.00904	CbGeAlD
Gefitinib—Hypoxia—Methotrexate—colon cancer	0.000269	0.00528	CcSEcCtD
Gefitinib—Dermatitis exfoliative—Irinotecan—colon cancer	0.000264	0.00518	CcSEcCtD
Gefitinib—Nail disorder—Methotrexate—colon cancer	0.000264	0.00517	CcSEcCtD
Gefitinib—Proteinuria—Capecitabine—colon cancer	0.000261	0.00513	CcSEcCtD
Gefitinib—MKNK2—lymph node—colon cancer	0.000259	0.0086	CbGeAlD
Gefitinib—IRAK1—lymph node—colon cancer	0.000259	0.0086	CbGeAlD
Gefitinib—Vandetanib—VEGFA—colon cancer	0.000258	0.0789	CrCbGaD
Gefitinib—Protein urine present—Capecitabine—colon cancer	0.000258	0.00506	CcSEcCtD
Gefitinib—MKNK1—lymph node—colon cancer	0.000256	0.00849	CbGeAlD
Gefitinib—Dermatitis bullous—Fluorouracil—colon cancer	0.00025	0.0049	CcSEcCtD
Gefitinib—ORM1—bone marrow—colon cancer	0.000247	0.00818	CbGeAlD
Gefitinib—MAP2K5—liver—colon cancer	0.000246	0.00814	CbGeAlD
Gefitinib—Ulcer—Capecitabine—colon cancer	0.000243	0.00476	CcSEcCtD
Gefitinib—Interstitial lung disease—Methotrexate—colon cancer	0.000242	0.00474	CcSEcCtD
Gefitinib—Dehydration—Vincristine—colon cancer	0.000238	0.00467	CcSEcCtD
Gefitinib—Dehydration—Irinotecan—colon cancer	0.000232	0.00455	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Vincristine—colon cancer	0.00023	0.00452	CcSEcCtD
Gefitinib—Hypokalaemia—Irinotecan—colon cancer	0.000227	0.00445	CcSEcCtD
Gefitinib—Melaena—Capecitabine—colon cancer	0.000224	0.0044	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Irinotecan—colon cancer	0.000224	0.0044	CcSEcCtD
Gefitinib—Pleural effusion—Methotrexate—colon cancer	0.000223	0.00438	CcSEcCtD
Gefitinib—Dry skin—Fluorouracil—colon cancer	0.000219	0.00429	CcSEcCtD
Gefitinib—Vandetanib—EGFR—colon cancer	0.000218	0.0666	CrCbGaD
Gefitinib—ABCB1—blood vessel—colon cancer	0.000214	0.00708	CbGeAlD
Gefitinib—Dry eye—Capecitabine—colon cancer	0.000212	0.00416	CcSEcCtD
Gefitinib—Pancreatitis—Irinotecan—colon cancer	0.000211	0.00414	CcSEcCtD
Gefitinib—STK10—lymph node—colon cancer	0.000211	0.00699	CbGeAlD
Gefitinib—Mouth ulceration—Capecitabine—colon cancer	0.000208	0.00407	CcSEcCtD
Gefitinib—Bosutinib—EGFR—colon cancer	0.000204	0.0623	CrCbGaD
Gefitinib—Lapatinib—ABCB1—colon cancer	0.000201	0.0614	CrCbGaD
Gefitinib—CYP1A1—epithelium—colon cancer	0.0002	0.00663	CbGeAlD
Gefitinib—Weight decreased—Vincristine—colon cancer	0.0002	0.00392	CcSEcCtD
Gefitinib—ORM1—liver—colon cancer	0.000199	0.00661	CbGeAlD
Gefitinib—Pneumonia—Vincristine—colon cancer	0.000198	0.00389	CcSEcCtD
Gefitinib—Weight decreased—Irinotecan—colon cancer	0.000195	0.00382	CcSEcCtD
Gefitinib—Proteinuria—Methotrexate—colon cancer	0.000195	0.00382	CcSEcCtD
Gefitinib—Pneumonia—Irinotecan—colon cancer	0.000193	0.00379	CcSEcCtD
Gefitinib—Thrombophlebitis—Capecitabine—colon cancer	0.000193	0.00378	CcSEcCtD
Gefitinib—Stomatitis—Vincristine—colon cancer	0.000192	0.00377	CcSEcCtD
Gefitinib—Protein urine present—Methotrexate—colon cancer	0.000192	0.00377	CcSEcCtD
Gefitinib—CYP2C19—digestive system—colon cancer	0.000189	0.00626	CbGeAlD
Gefitinib—MAP2K5—lymph node—colon cancer	0.000188	0.00624	CbGeAlD
Gefitinib—Stomatitis—Irinotecan—colon cancer	0.000187	0.00367	CcSEcCtD
Gefitinib—CYP1A1—renal system—colon cancer	0.000186	0.00615	CbGeAlD
Gefitinib—Hepatic failure—Capecitabine—colon cancer	0.000186	0.00364	CcSEcCtD
Gefitinib—Pneumonia—Fluorouracil—colon cancer	0.000185	0.00363	CcSEcCtD
Gefitinib—Eye pain—Capecitabine—colon cancer	0.000185	0.00362	CcSEcCtD
Gefitinib—Infestation—Fluorouracil—colon cancer	0.000184	0.00361	CcSEcCtD
Gefitinib—Infestation NOS—Fluorouracil—colon cancer	0.000184	0.00361	CcSEcCtD
Gefitinib—CYP3A5—renal system—colon cancer	0.000182	0.00602	CbGeAlD
Gefitinib—Ulcer—Methotrexate—colon cancer	0.000181	0.00355	CcSEcCtD
Gefitinib—Stomatitis—Fluorouracil—colon cancer	0.000179	0.00352	CcSEcCtD
Gefitinib—Conjunctivitis—Fluorouracil—colon cancer	0.000179	0.00351	CcSEcCtD
Gefitinib—Dermatitis exfoliative—Capecitabine—colon cancer	0.000177	0.00347	CcSEcCtD
Gefitinib—Atrial fibrillation—Capecitabine—colon cancer	0.000176	0.00345	CcSEcCtD
Gefitinib—ALB—liver—colon cancer	0.000175	0.0058	CbGeAlD
Gefitinib—Urinary tract disorder—Vincristine—colon cancer	0.000175	0.00343	CcSEcCtD
Gefitinib—Dermatitis bullous—Capecitabine—colon cancer	0.000174	0.00342	CcSEcCtD
Gefitinib—Respiratory failure—Methotrexate—colon cancer	0.000174	0.00342	CcSEcCtD
Gefitinib—Urethral disorder—Vincristine—colon cancer	0.000173	0.0034	CcSEcCtD
Gefitinib—Epistaxis—Fluorouracil—colon cancer	0.000173	0.0034	CcSEcCtD
Gefitinib—Haemoglobin—Irinotecan—colon cancer	0.000173	0.0034	CcSEcCtD
Gefitinib—Haemorrhage—Irinotecan—colon cancer	0.000172	0.00338	CcSEcCtD
Gefitinib—Melaena—Methotrexate—colon cancer	0.000167	0.00328	CcSEcCtD
Gefitinib—Cystitis noninfective—Methotrexate—colon cancer	0.000167	0.00328	CcSEcCtD
Gefitinib—CYP2C19—vagina—colon cancer	0.000167	0.00553	CbGeAlD
Gefitinib—Haemoglobin—Fluorouracil—colon cancer	0.000166	0.00325	CcSEcCtD
Gefitinib—Cystitis—Methotrexate—colon cancer	0.000165	0.00324	CcSEcCtD
Gefitinib—Haemorrhage—Fluorouracil—colon cancer	0.000165	0.00324	CcSEcCtD
Gefitinib—Cardiac disorder—Vincristine—colon cancer	0.000164	0.00322	CcSEcCtD
Gefitinib—Angiopathy—Vincristine—colon cancer	0.000161	0.00315	CcSEcCtD
Gefitinib—Cardiac disorder—Irinotecan—colon cancer	0.00016	0.00314	CcSEcCtD
Gefitinib—Mediastinal disorder—Vincristine—colon cancer	0.000159	0.00313	CcSEcCtD
Gefitinib—Alopecia—Vincristine—colon cancer	0.000156	0.00307	CcSEcCtD
Gefitinib—Angiopathy—Irinotecan—colon cancer	0.000156	0.00307	CcSEcCtD
Gefitinib—Mediastinal disorder—Irinotecan—colon cancer	0.000155	0.00305	CcSEcCtD
Gefitinib—Dehydration—Capecitabine—colon cancer	0.000155	0.00304	CcSEcCtD
Gefitinib—Bladder pain—Methotrexate—colon cancer	0.000155	0.00303	CcSEcCtD
Gefitinib—Mouth ulceration—Methotrexate—colon cancer	0.000155	0.00303	CcSEcCtD
Gefitinib—Arrhythmia—Irinotecan—colon cancer	0.000154	0.00302	CcSEcCtD
Gefitinib—ORM1—lymph node—colon cancer	0.000153	0.00507	CbGeAlD
Gefitinib—Dry skin—Capecitabine—colon cancer	0.000153	0.003	CcSEcCtD
Gefitinib—CYP1A1—digestive system—colon cancer	0.000152	0.00505	CbGeAlD
Gefitinib—Alopecia—Irinotecan—colon cancer	0.000152	0.00299	CcSEcCtD
Gefitinib—Hypokalaemia—Capecitabine—colon cancer	0.000152	0.00298	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Capecitabine—colon cancer	0.00015	0.00295	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Capecitabine—colon cancer	0.00015	0.00295	CcSEcCtD
Gefitinib—CYP3A5—digestive system—colon cancer	0.000149	0.00494	CbGeAlD
Gefitinib—ABCG2—bone marrow—colon cancer	0.000148	0.0049	CbGeAlD
Gefitinib—Arrhythmia—Fluorouracil—colon cancer	0.000147	0.00289	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Capecitabine—colon cancer	0.000147	0.00289	CcSEcCtD
Gefitinib—CYP2C9—digestive system—colon cancer	0.000147	0.00486	CbGeAlD
Gefitinib—Alopecia—Fluorouracil—colon cancer	0.000146	0.00286	CcSEcCtD
Gefitinib—Thrombophlebitis—Methotrexate—colon cancer	0.000143	0.00281	CcSEcCtD
Gefitinib—Anaemia—Vincristine—colon cancer	0.000142	0.00279	CcSEcCtD
Gefitinib—Afatinib—ABCB1—colon cancer	0.000142	0.0435	CrCbGaD
Gefitinib—ABCG2—vagina—colon cancer	0.000142	0.00469	CbGeAlD
Gefitinib—CYP2C19—liver—colon cancer	0.000141	0.00467	CbGeAlD
Gefitinib—Anaemia—Irinotecan—colon cancer	0.000139	0.00272	CcSEcCtD
Gefitinib—Hepatic failure—Methotrexate—colon cancer	0.000138	0.00271	CcSEcCtD
Gefitinib—CYP3A4—renal system—colon cancer	0.000136	0.00452	CbGeAlD
Gefitinib—Malaise—Irinotecan—colon cancer	0.000135	0.00265	CcSEcCtD
Gefitinib—CYP1A1—vagina—colon cancer	0.000134	0.00446	CbGeAlD
Gefitinib—ALB—lymph node—colon cancer	0.000134	0.00444	CbGeAlD
Gefitinib—CYP2D6—renal system—colon cancer	0.000134	0.00444	CbGeAlD
Gefitinib—Anaemia—Fluorouracil—colon cancer	0.000133	0.00261	CcSEcCtD
Gefitinib—Dermatitis exfoliative—Methotrexate—colon cancer	0.000132	0.00258	CcSEcCtD
Gefitinib—CYP3A5—vagina—colon cancer	0.000132	0.00436	CbGeAlD
Gefitinib—Cough—Irinotecan—colon cancer	0.000131	0.00257	CcSEcCtD
Gefitinib—Weight decreased—Capecitabine—colon cancer	0.00013	0.00256	CcSEcCtD
Gefitinib—Pneumonia—Capecitabine—colon cancer	0.000129	0.00254	CcSEcCtD
Gefitinib—Infestation—Capecitabine—colon cancer	0.000128	0.00252	CcSEcCtD
Gefitinib—Infestation NOS—Capecitabine—colon cancer	0.000128	0.00252	CcSEcCtD
Gefitinib—ABCB1—embryo—colon cancer	0.000127	0.00422	CbGeAlD
Gefitinib—Stevens-Johnson syndrome—Capecitabine—colon cancer	0.000127	0.0025	CcSEcCtD
Gefitinib—Stomatitis—Capecitabine—colon cancer	0.000125	0.00246	CcSEcCtD
Gefitinib—Infection—Vincristine—colon cancer	0.000125	0.00245	CcSEcCtD
Gefitinib—Conjunctivitis—Capecitabine—colon cancer	0.000125	0.00245	CcSEcCtD
Gefitinib—Nervous system disorder—Vincristine—colon cancer	0.000123	0.00242	CcSEcCtD
Gefitinib—Thrombocytopenia—Vincristine—colon cancer	0.000123	0.00242	CcSEcCtD
Gefitinib—Haematuria—Capecitabine—colon cancer	0.000123	0.0024	CcSEcCtD
Gefitinib—Infection—Irinotecan—colon cancer	0.000122	0.00239	CcSEcCtD
Gefitinib—Hepatobiliary disease—Capecitabine—colon cancer	0.000122	0.00238	CcSEcCtD
Gefitinib—Epistaxis—Capecitabine—colon cancer	0.000121	0.00238	CcSEcCtD
Gefitinib—Shock—Irinotecan—colon cancer	0.00012	0.00236	CcSEcCtD
Gefitinib—Nervous system disorder—Irinotecan—colon cancer	0.00012	0.00236	CcSEcCtD
Gefitinib—Thrombocytopenia—Irinotecan—colon cancer	0.00012	0.00235	CcSEcCtD
Gefitinib—Anorexia—Vincristine—colon cancer	0.00012	0.00235	CcSEcCtD
Gefitinib—ABCG2—liver—colon cancer	0.00012	0.00396	CbGeAlD
Gefitinib—Hypotension—Vincristine—colon cancer	0.000117	0.0023	CcSEcCtD
Gefitinib—Anorexia—Irinotecan—colon cancer	0.000117	0.00229	CcSEcCtD
Gefitinib—Infection—Fluorouracil—colon cancer	0.000116	0.00229	CcSEcCtD
Gefitinib—Haemoglobin—Capecitabine—colon cancer	0.000116	0.00227	CcSEcCtD
Gefitinib—Haemorrhage—Capecitabine—colon cancer	0.000115	0.00226	CcSEcCtD
Gefitinib—Hepatitis—Capecitabine—colon cancer	0.000115	0.00226	CcSEcCtD
Gefitinib—Nervous system disorder—Fluorouracil—colon cancer	0.000115	0.00226	CcSEcCtD
Gefitinib—Thrombocytopenia—Fluorouracil—colon cancer	0.000115	0.00225	CcSEcCtD
Gefitinib—Hypotension—Irinotecan—colon cancer	0.000114	0.00224	CcSEcCtD
Gefitinib—Urinary tract disorder—Capecitabine—colon cancer	0.000114	0.00223	CcSEcCtD
Gefitinib—Oedema peripheral—Capecitabine—colon cancer	0.000114	0.00223	CcSEcCtD
Gefitinib—CYP1A1—liver—colon cancer	0.000113	0.00376	CbGeAlD
Gefitinib—Urethral disorder—Capecitabine—colon cancer	0.000113	0.00222	CcSEcCtD
Gefitinib—Anorexia—Fluorouracil—colon cancer	0.000112	0.00219	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Methotrexate—colon cancer	0.000112	0.00219	CcSEcCtD
Gefitinib—CYP3A4—digestive system—colon cancer	0.000112	0.0037	CbGeAlD
Gefitinib—CYP3A5—liver—colon cancer	0.000111	0.00368	CbGeAlD
Gefitinib—CYP2D6—digestive system—colon cancer	0.00011	0.00364	CbGeAlD
Gefitinib—Hypotension—Fluorouracil—colon cancer	0.00011	0.00215	CcSEcCtD
Gefitinib—Decreased appetite—Vincristine—colon cancer	0.000109	0.00214	CcSEcCtD
Gefitinib—CYP2C9—liver—colon cancer	0.000109	0.00362	CbGeAlD
Gefitinib—Dyspnoea—Irinotecan—colon cancer	0.000109	0.00214	CcSEcCtD
Gefitinib—Erythema multiforme—Capecitabine—colon cancer	0.000109	0.00214	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Vincristine—colon cancer	0.000109	0.00213	CcSEcCtD
Gefitinib—Fatigue—Vincristine—colon cancer	0.000108	0.00213	CcSEcCtD
Gefitinib—Eye disorder—Capecitabine—colon cancer	0.000108	0.00211	CcSEcCtD
Gefitinib—Pain—Vincristine—colon cancer	0.000108	0.00211	CcSEcCtD
Gefitinib—Constipation—Vincristine—colon cancer	0.000108	0.00211	CcSEcCtD
Gefitinib—Cardiac disorder—Capecitabine—colon cancer	0.000107	0.0021	CcSEcCtD
Gefitinib—Decreased appetite—Irinotecan—colon cancer	0.000106	0.00209	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Irinotecan—colon cancer	0.000106	0.00207	CcSEcCtD
Gefitinib—Fatigue—Irinotecan—colon cancer	0.000106	0.00207	CcSEcCtD
Gefitinib—Pancreatitis—Methotrexate—colon cancer	0.000105	0.00206	CcSEcCtD
Gefitinib—Pain—Irinotecan—colon cancer	0.000105	0.00205	CcSEcCtD
Gefitinib—Constipation—Irinotecan—colon cancer	0.000105	0.00205	CcSEcCtD
Gefitinib—Angiopathy—Capecitabine—colon cancer	0.000105	0.00205	CcSEcCtD
Gefitinib—Dyspnoea—Fluorouracil—colon cancer	0.000105	0.00205	CcSEcCtD
Gefitinib—ABCB1—epithelium—colon cancer	0.000104	0.00345	CbGeAlD
Gefitinib—Mediastinal disorder—Capecitabine—colon cancer	0.000104	0.00204	CcSEcCtD
Gefitinib—Arrhythmia—Capecitabine—colon cancer	0.000103	0.00202	CcSEcCtD
Gefitinib—Gastrointestinal pain—Vincristine—colon cancer	0.000103	0.00202	CcSEcCtD
Gefitinib—Decreased appetite—Fluorouracil—colon cancer	0.000102	0.002	CcSEcCtD
Gefitinib—Alopecia—Capecitabine—colon cancer	0.000102	0.002	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000101	0.00199	CcSEcCtD
Gefitinib—Erlotinib—ABCB1—colon cancer	0.000101	0.0307	CrCbGaD
Gefitinib—Malnutrition—Capecitabine—colon cancer	0.0001	0.00197	CcSEcCtD
Gefitinib—Pain—Fluorouracil—colon cancer	0.0001	0.00197	CcSEcCtD
Gefitinib—Gastrointestinal pain—Irinotecan—colon cancer	0.0001	0.00196	CcSEcCtD
Gefitinib—Body temperature increased—Vincristine—colon cancer	9.94e-05	0.00195	CcSEcCtD
Gefitinib—Abdominal pain—Vincristine—colon cancer	9.94e-05	0.00195	CcSEcCtD
Gefitinib—Body temperature increased—Irinotecan—colon cancer	9.68e-05	0.0019	CcSEcCtD
Gefitinib—Abdominal pain—Irinotecan—colon cancer	9.68e-05	0.0019	CcSEcCtD
Gefitinib—ABCB1—renal system—colon cancer	9.64e-05	0.0032	CbGeAlD
Gefitinib—Pneumonia—Methotrexate—colon cancer	9.62e-05	0.00189	CcSEcCtD
Gefitinib—Infestation NOS—Methotrexate—colon cancer	9.56e-05	0.00188	CcSEcCtD
Gefitinib—Infestation—Methotrexate—colon cancer	9.56e-05	0.00188	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Methotrexate—colon cancer	9.48e-05	0.00186	CcSEcCtD
Gefitinib—Stomatitis—Methotrexate—colon cancer	9.32e-05	0.00183	CcSEcCtD
Gefitinib—Urticaria—Fluorouracil—colon cancer	9.32e-05	0.00183	CcSEcCtD
Gefitinib—Conjunctivitis—Methotrexate—colon cancer	9.3e-05	0.00182	CcSEcCtD
Gefitinib—Anaemia—Capecitabine—colon cancer	9.28e-05	0.00182	CcSEcCtD
Gefitinib—Body temperature increased—Fluorouracil—colon cancer	9.27e-05	0.00182	CcSEcCtD
Gefitinib—Hypersensitivity—Vincristine—colon cancer	9.26e-05	0.00182	CcSEcCtD
Gefitinib—ABCG2—lymph node—colon cancer	9.16e-05	0.00304	CbGeAlD
Gefitinib—Haematuria—Methotrexate—colon cancer	9.12e-05	0.00179	CcSEcCtD
Gefitinib—Malaise—Capecitabine—colon cancer	9.05e-05	0.00178	CcSEcCtD
Gefitinib—Hepatobiliary disease—Methotrexate—colon cancer	9.05e-05	0.00177	CcSEcCtD
Gefitinib—Epistaxis—Methotrexate—colon cancer	9.02e-05	0.00177	CcSEcCtD
Gefitinib—Hypersensitivity—Irinotecan—colon cancer	9.02e-05	0.00177	CcSEcCtD
Gefitinib—Asthenia—Vincristine—colon cancer	9.02e-05	0.00177	CcSEcCtD
Gefitinib—Asthenia—Irinotecan—colon cancer	8.78e-05	0.00172	CcSEcCtD
Gefitinib—Cough—Capecitabine—colon cancer	8.76e-05	0.00172	CcSEcCtD
Gefitinib—CYP1A1—lymph node—colon cancer	8.7e-05	0.00288	CbGeAlD
Gefitinib—Hypersensitivity—Fluorouracil—colon cancer	8.64e-05	0.0017	CcSEcCtD
Gefitinib—Haemoglobin—Methotrexate—colon cancer	8.63e-05	0.00169	CcSEcCtD
Gefitinib—Diarrhoea—Vincristine—colon cancer	8.6e-05	0.00169	CcSEcCtD
Gefitinib—Hepatitis—Methotrexate—colon cancer	8.59e-05	0.00168	CcSEcCtD
Gefitinib—Haemorrhage—Methotrexate—colon cancer	8.59e-05	0.00168	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	8.49e-05	0.00167	CcSEcCtD
Gefitinib—Urinary tract disorder—Methotrexate—colon cancer	8.48e-05	0.00166	CcSEcCtD
Gefitinib—Urethral disorder—Methotrexate—colon cancer	8.42e-05	0.00165	CcSEcCtD
Gefitinib—Diarrhoea—Irinotecan—colon cancer	8.38e-05	0.00164	CcSEcCtD
Gefitinib—Dry mouth—Capecitabine—colon cancer	8.36e-05	0.00164	CcSEcCtD
Gefitinib—CYP3A4—liver—colon cancer	8.33e-05	0.00276	CbGeAlD
Gefitinib—Pruritus—Fluorouracil—colon cancer	8.3e-05	0.00163	CcSEcCtD
Gefitinib—CYP2D6—liver—colon cancer	8.19e-05	0.00272	CbGeAlD
Gefitinib—Infection—Capecitabine—colon cancer	8.14e-05	0.0016	CcSEcCtD
Gefitinib—Erythema multiforme—Methotrexate—colon cancer	8.12e-05	0.00159	CcSEcCtD
Gefitinib—Shock—Capecitabine—colon cancer	8.06e-05	0.00158	CcSEcCtD
Gefitinib—Nervous system disorder—Capecitabine—colon cancer	8.04e-05	0.00158	CcSEcCtD
Gefitinib—Eye disorder—Methotrexate—colon cancer	8.02e-05	0.00157	CcSEcCtD
Gefitinib—Diarrhoea—Fluorouracil—colon cancer	8.02e-05	0.00157	CcSEcCtD
Gefitinib—Thrombocytopenia—Capecitabine—colon cancer	8.02e-05	0.00157	CcSEcCtD
Gefitinib—ABCB1—lymphoid tissue—colon cancer	8.01e-05	0.00265	CbGeAlD
Gefitinib—Vomiting—Vincristine—colon cancer	7.99e-05	0.00157	CcSEcCtD
Gefitinib—Cardiac disorder—Methotrexate—colon cancer	7.97e-05	0.00156	CcSEcCtD
Gefitinib—Skin disorder—Capecitabine—colon cancer	7.96e-05	0.00156	CcSEcCtD
Gefitinib—Rash—Vincristine—colon cancer	7.93e-05	0.00156	CcSEcCtD
Gefitinib—Dermatitis—Vincristine—colon cancer	7.92e-05	0.00155	CcSEcCtD
Gefitinib—ABCB1—digestive system—colon cancer	7.91e-05	0.00262	CbGeAlD
Gefitinib—Anorexia—Capecitabine—colon cancer	7.81e-05	0.00153	CcSEcCtD
Gefitinib—Angiopathy—Methotrexate—colon cancer	7.79e-05	0.00153	CcSEcCtD
Gefitinib—Vomiting—Irinotecan—colon cancer	7.78e-05	0.00153	CcSEcCtD
Gefitinib—Mediastinal disorder—Methotrexate—colon cancer	7.74e-05	0.00152	CcSEcCtD
Gefitinib—Rash—Irinotecan—colon cancer	7.72e-05	0.00151	CcSEcCtD
Gefitinib—Dermatitis—Irinotecan—colon cancer	7.71e-05	0.00151	CcSEcCtD
Gefitinib—Hypotension—Capecitabine—colon cancer	7.66e-05	0.0015	CcSEcCtD
Gefitinib—Alopecia—Methotrexate—colon cancer	7.59e-05	0.00149	CcSEcCtD
Gefitinib—Malnutrition—Methotrexate—colon cancer	7.47e-05	0.00147	CcSEcCtD
Gefitinib—Nausea—Vincristine—colon cancer	7.47e-05	0.00147	CcSEcCtD
Gefitinib—Vomiting—Fluorouracil—colon cancer	7.46e-05	0.00146	CcSEcCtD
Gefitinib—Rash—Fluorouracil—colon cancer	7.39e-05	0.00145	CcSEcCtD
Gefitinib—Dermatitis—Fluorouracil—colon cancer	7.39e-05	0.00145	CcSEcCtD
Gefitinib—Dyspnoea—Capecitabine—colon cancer	7.31e-05	0.00143	CcSEcCtD
Gefitinib—ABCB1—bone marrow—colon cancer	7.29e-05	0.00242	CbGeAlD
Gefitinib—Nausea—Irinotecan—colon cancer	7.27e-05	0.00143	CcSEcCtD
Gefitinib—Decreased appetite—Capecitabine—colon cancer	7.12e-05	0.0014	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Capecitabine—colon cancer	7.07e-05	0.00139	CcSEcCtD
Gefitinib—Fatigue—Capecitabine—colon cancer	7.06e-05	0.00139	CcSEcCtD
Gefitinib—Pain—Capecitabine—colon cancer	7.01e-05	0.00137	CcSEcCtD
Gefitinib—Constipation—Capecitabine—colon cancer	7.01e-05	0.00137	CcSEcCtD
Gefitinib—ABCB1—vagina—colon cancer	6.99e-05	0.00232	CbGeAlD
Gefitinib—Nausea—Fluorouracil—colon cancer	6.97e-05	0.00137	CcSEcCtD
Gefitinib—Anaemia—Methotrexate—colon cancer	6.91e-05	0.00136	CcSEcCtD
Gefitinib—Malaise—Methotrexate—colon cancer	6.74e-05	0.00132	CcSEcCtD
Gefitinib—Gastrointestinal pain—Capecitabine—colon cancer	6.7e-05	0.00131	CcSEcCtD
Gefitinib—Cough—Methotrexate—colon cancer	6.52e-05	0.00128	CcSEcCtD
Gefitinib—Urticaria—Capecitabine—colon cancer	6.51e-05	0.00128	CcSEcCtD
Gefitinib—Abdominal pain—Capecitabine—colon cancer	6.48e-05	0.00127	CcSEcCtD
Gefitinib—Body temperature increased—Capecitabine—colon cancer	6.48e-05	0.00127	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	6.32e-05	0.00124	CcSEcCtD
Gefitinib—Bosutinib—ABCB1—colon cancer	6.2e-05	0.0189	CrCbGaD
Gefitinib—Infection—Methotrexate—colon cancer	6.06e-05	0.00119	CcSEcCtD
Gefitinib—Hypersensitivity—Capecitabine—colon cancer	6.04e-05	0.00118	CcSEcCtD
Gefitinib—Nervous system disorder—Methotrexate—colon cancer	5.98e-05	0.00117	CcSEcCtD
Gefitinib—Thrombocytopenia—Methotrexate—colon cancer	5.97e-05	0.00117	CcSEcCtD
Gefitinib—Skin disorder—Methotrexate—colon cancer	5.93e-05	0.00116	CcSEcCtD
Gefitinib—ABCB1—liver—colon cancer	5.89e-05	0.00195	CbGeAlD
Gefitinib—Asthenia—Capecitabine—colon cancer	5.88e-05	0.00115	CcSEcCtD
Gefitinib—Anorexia—Methotrexate—colon cancer	5.81e-05	0.00114	CcSEcCtD
Gefitinib—Pruritus—Capecitabine—colon cancer	5.8e-05	0.00114	CcSEcCtD
Gefitinib—Hypotension—Methotrexate—colon cancer	5.7e-05	0.00112	CcSEcCtD
Gefitinib—Diarrhoea—Capecitabine—colon cancer	5.61e-05	0.0011	CcSEcCtD
Gefitinib—Dyspnoea—Methotrexate—colon cancer	5.44e-05	0.00107	CcSEcCtD
Gefitinib—Decreased appetite—Methotrexate—colon cancer	5.3e-05	0.00104	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Methotrexate—colon cancer	5.27e-05	0.00103	CcSEcCtD
Gefitinib—Fatigue—Methotrexate—colon cancer	5.26e-05	0.00103	CcSEcCtD
Gefitinib—Pain—Methotrexate—colon cancer	5.22e-05	0.00102	CcSEcCtD
Gefitinib—Vomiting—Capecitabine—colon cancer	5.21e-05	0.00102	CcSEcCtD
Gefitinib—Rash—Capecitabine—colon cancer	5.17e-05	0.00101	CcSEcCtD
Gefitinib—Dermatitis—Capecitabine—colon cancer	5.16e-05	0.00101	CcSEcCtD
Gefitinib—Gastrointestinal pain—Methotrexate—colon cancer	4.99e-05	0.000979	CcSEcCtD
Gefitinib—Nausea—Capecitabine—colon cancer	4.87e-05	0.000955	CcSEcCtD
Gefitinib—Urticaria—Methotrexate—colon cancer	4.85e-05	0.000951	CcSEcCtD
Gefitinib—Abdominal pain—Methotrexate—colon cancer	4.82e-05	0.000946	CcSEcCtD
Gefitinib—Body temperature increased—Methotrexate—colon cancer	4.82e-05	0.000946	CcSEcCtD
Gefitinib—ABCB1—lymph node—colon cancer	4.52e-05	0.0015	CbGeAlD
Gefitinib—Hypersensitivity—Methotrexate—colon cancer	4.49e-05	0.000882	CcSEcCtD
Gefitinib—Asthenia—Methotrexate—colon cancer	4.38e-05	0.000859	CcSEcCtD
Gefitinib—Pruritus—Methotrexate—colon cancer	4.32e-05	0.000847	CcSEcCtD
Gefitinib—Diarrhoea—Methotrexate—colon cancer	4.17e-05	0.000819	CcSEcCtD
Gefitinib—Vomiting—Methotrexate—colon cancer	3.88e-05	0.000761	CcSEcCtD
Gefitinib—Rash—Methotrexate—colon cancer	3.85e-05	0.000755	CcSEcCtD
Gefitinib—Dermatitis—Methotrexate—colon cancer	3.84e-05	0.000754	CcSEcCtD
Gefitinib—Nausea—Methotrexate—colon cancer	3.62e-05	0.000711	CcSEcCtD
Gefitinib—IRAK1—Immune System—CTNNB1—colon cancer	5.18e-06	8.68e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—NRAS—colon cancer	5.17e-06	8.66e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—SRC—colon cancer	5.16e-06	8.65e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—CDKN1A—colon cancer	5.15e-06	8.64e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—FGFR3—colon cancer	5.12e-06	8.59e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—ABCB1—colon cancer	5.1e-06	8.55e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—KRAS—colon cancer	5.08e-06	8.51e-05	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—PIK3CA—colon cancer	5.07e-06	8.5e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CDKN1A—colon cancer	5.06e-06	8.48e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—KRAS—colon cancer	5.04e-06	8.44e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—TYMS—colon cancer	5.01e-06	8.4e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	4.99e-06	8.37e-05	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—AKT1—colon cancer	4.99e-06	8.37e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—NRAS—colon cancer	4.99e-06	8.37e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—NRAS—colon cancer	4.96e-06	8.32e-05	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—HRAS—colon cancer	4.96e-06	8.32e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—APC—colon cancer	4.93e-06	8.26e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—EGFR—colon cancer	4.93e-06	8.26e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PPARG—colon cancer	4.92e-06	8.24e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—EP300—colon cancer	4.9e-06	8.22e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	4.83e-06	8.1e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—EP300—colon cancer	4.81e-06	8.07e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—HRAS—colon cancer	4.79e-06	8.03e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—SRC—colon cancer	4.77e-06	7.99e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—APC—colon cancer	4.7e-06	7.89e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CDH1—colon cancer	4.69e-06	7.86e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—SRC—colon cancer	4.68e-06	7.84e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—PIK3CA—colon cancer	4.66e-06	7.82e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—KRAS—colon cancer	4.65e-06	7.8e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—MYC—colon cancer	4.65e-06	7.79e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—VEGFA—colon cancer	4.64e-06	7.79e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—TGFB1—colon cancer	4.64e-06	7.78e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—BRAF—colon cancer	4.63e-06	7.76e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—NRAS—colon cancer	4.59e-06	7.69e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—EGFR—colon cancer	4.55e-06	7.62e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—TP53—colon cancer	4.51e-06	7.56e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—NRAS—colon cancer	4.5e-06	7.55e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—KRAS—colon cancer	4.45e-06	7.46e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—BRAF—colon cancer	4.42e-06	7.41e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—colon cancer	4.41e-06	7.4e-05	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—AKT1—colon cancer	4.38e-06	7.34e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CASP3—colon cancer	4.33e-06	7.25e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—HRAS—colon cancer	4.32e-06	7.23e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—KRAS—colon cancer	4.3e-06	7.2e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—HRAS—colon cancer	4.28e-06	7.18e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—PIK3CA—colon cancer	4.27e-06	7.17e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—MYC—colon cancer	4.27e-06	7.16e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—KRAS—colon cancer	4.27e-06	7.16e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—TGFB1—colon cancer	4.26e-06	7.15e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	4.24e-06	7.11e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—AKT1—colon cancer	4.23e-06	7.09e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CCND1—colon cancer	4.21e-06	7.06e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—EGFR—colon cancer	4.18e-06	7.01e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CTNNB1—colon cancer	4.17e-06	6.99e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CASP3—colon cancer	4.17e-06	6.99e-05	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—AKT1—colon cancer	4.14e-06	6.95e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—EGFR—colon cancer	4.1e-06	6.87e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—PIK3CA—colon cancer	4.09e-06	6.85e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	4.08e-06	6.84e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CDKN1A—colon cancer	4.07e-06	6.83e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CCND1—colon cancer	4.06e-06	6.8e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—colon cancer	4.03e-06	6.75e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CTNNB1—colon cancer	4.02e-06	6.74e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—HRAS—colon cancer	3.95e-06	6.63e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—KRAS—colon cancer	3.95e-06	6.62e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—PIK3CA—colon cancer	3.95e-06	6.62e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CDKN1A—colon cancer	3.93e-06	6.58e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—PIK3CA—colon cancer	3.92e-06	6.58e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—EP300—colon cancer	3.88e-06	6.5e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—KRAS—colon cancer	3.87e-06	6.49e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	3.87e-06	6.49e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—AKT1—colon cancer	3.81e-06	6.39e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—HRAS—colon cancer	3.78e-06	6.34e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—AKT1—colon cancer	3.78e-06	6.34e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—SRC—colon cancer	3.77e-06	6.32e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—EP300—colon cancer	3.74e-06	6.26e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—VEGFA—colon cancer	3.67e-06	6.15e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—ABCB1—colon cancer	3.66e-06	6.13e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—HRAS—colon cancer	3.65e-06	6.12e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—SRC—colon cancer	3.63e-06	6.09e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—HRAS—colon cancer	3.63e-06	6.09e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—PIK3CA—colon cancer	3.63e-06	6.08e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—NRAS—colon cancer	3.63e-06	6.08e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—TYMS—colon cancer	3.59e-06	6.02e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—FGFR3—colon cancer	3.59e-06	6.01e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—PTGS2—colon cancer	3.57e-06	5.99e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—PIK3CA—colon cancer	3.56e-06	5.97e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PPARG—colon cancer	3.55e-06	5.95e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—VEGFA—colon cancer	3.54e-06	5.93e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—EP300—colon cancer	3.53e-06	5.93e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—EP300—colon cancer	3.53e-06	5.92e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—TP53—colon cancer	3.51e-06	5.88e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—NRAS—colon cancer	3.5e-06	5.86e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—AKT1—colon cancer	3.49e-06	5.85e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	3.47e-06	5.82e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CASP3—colon cancer	3.47e-06	5.82e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CTNNB1—colon cancer	3.46e-06	5.8e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—ABCB1—colon cancer	3.45e-06	5.79e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—SRC—colon cancer	3.44e-06	5.76e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—TYMS—colon cancer	3.39e-06	5.69e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CDKN1A—colon cancer	3.38e-06	5.67e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CCND1—colon cancer	3.38e-06	5.67e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MYC—colon cancer	3.38e-06	5.66e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TGFB1—colon cancer	3.37e-06	5.65e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—HRAS—colon cancer	3.36e-06	5.63e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—VEGFA—colon cancer	3.35e-06	5.61e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CTNNB1—colon cancer	3.35e-06	5.61e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—AKT1—colon cancer	3.34e-06	5.6e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—NRAS—colon cancer	3.31e-06	5.54e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—EGFR—colon cancer	3.3e-06	5.54e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—APC—colon cancer	3.29e-06	5.52e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—NRAS—colon cancer	3.29e-06	5.52e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—HRAS—colon cancer	3.29e-06	5.52e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CDKN1A—colon cancer	3.27e-06	5.48e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MYC—colon cancer	3.26e-06	5.46e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TGFB1—colon cancer	3.25e-06	5.44e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—AKT1—colon cancer	3.22e-06	5.41e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—EP300—colon cancer	3.22e-06	5.39e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—EP300—colon cancer	3.22e-06	5.39e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—AKT1—colon cancer	3.21e-06	5.37e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—CTNNB1—colon cancer	3.2e-06	5.36e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—EGFR—colon cancer	3.18e-06	5.34e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	3.17e-06	5.31e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—ABCB1—colon cancer	3.15e-06	5.28e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—SRC—colon cancer	3.13e-06	5.24e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—CDKN1A—colon cancer	3.12e-06	5.23e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—KRAS—colon cancer	3.12e-06	5.23e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—EP300—colon cancer	3.11e-06	5.21e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—BRAF—colon cancer	3.1e-06	5.19e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—TYMS—colon cancer	3.09e-06	5.18e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TGFB1—colon cancer	3.07e-06	5.15e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—SRC—colon cancer	3.02e-06	5.07e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—NRAS—colon cancer	3.01e-06	5.05e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—KRAS—colon cancer	3.01e-06	5.04e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—EP300—colon cancer	2.97e-06	4.98e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—AKT1—colon cancer	2.96e-06	4.97e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—VEGFA—colon cancer	2.95e-06	4.94e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—NRAS—colon cancer	2.91e-06	4.88e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—AKT1—colon cancer	2.91e-06	4.87e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—colon cancer	2.89e-06	4.84e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—SRC—colon cancer	2.89e-06	4.84e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—PIK3CA—colon cancer	2.87e-06	4.81e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—KRAS—colon cancer	2.85e-06	4.77e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—KRAS—colon cancer	2.83e-06	4.75e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ABCB1—colon cancer	2.83e-06	4.74e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PTGS2—colon cancer	2.79e-06	4.68e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—NRAS—colon cancer	2.78e-06	4.66e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—TYMS—colon cancer	2.78e-06	4.65e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TP53—colon cancer	2.77e-06	4.65e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—PIK3CA—colon cancer	2.76e-06	4.63e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MYC—colon cancer	2.71e-06	4.54e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—TYMS—colon cancer	2.71e-06	4.54e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TGFB1—colon cancer	2.7e-06	4.53e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TP53—colon cancer	2.67e-06	4.48e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—HRAS—colon cancer	2.65e-06	4.45e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—EGFR—colon cancer	2.65e-06	4.44e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—colon cancer	2.63e-06	4.42e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—PIK3CA—colon cancer	2.61e-06	4.38e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	2.61e-06	4.38e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—PIK3CA—colon cancer	2.6e-06	4.37e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ABCB1—colon cancer	2.6e-06	4.36e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—KRAS—colon cancer	2.59e-06	4.34e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—MYC—colon cancer	2.59e-06	4.34e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—TGFB1—colon cancer	2.58e-06	4.33e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ABCB1—colon cancer	2.58e-06	4.32e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—HRAS—colon cancer	2.56e-06	4.29e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—TYMS—colon cancer	2.55e-06	4.28e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PPARG—colon cancer	2.54e-06	4.26e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—TYMS—colon cancer	2.53e-06	4.24e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TP53—colon cancer	2.53e-06	4.24e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—KRAS—colon cancer	2.5e-06	4.2e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—HRAS—colon cancer	2.42e-06	4.06e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—HRAS—colon cancer	2.41e-06	4.04e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PPARG—colon cancer	2.4e-06	4.03e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—KRAS—colon cancer	2.39e-06	4.01e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	2.38e-06	3.99e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—PIK3CA—colon cancer	2.38e-06	3.99e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—AKT1—colon cancer	2.34e-06	3.93e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—EP300—colon cancer	2.32e-06	3.89e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CASP3—colon cancer	2.32e-06	3.89e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—PIK3CA—colon cancer	2.3e-06	3.86e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCND1—colon cancer	2.26e-06	3.79e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—AKT1—colon cancer	2.26e-06	3.79e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CTNNB1—colon cancer	2.24e-06	3.75e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TP53—colon cancer	2.23e-06	3.73e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HRAS—colon cancer	2.2e-06	3.69e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—PIK3CA—colon cancer	2.2e-06	3.68e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PPARG—colon cancer	2.19e-06	3.67e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CDKN1A—colon cancer	2.19e-06	3.66e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	2.14e-06	3.58e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—AKT1—colon cancer	2.14e-06	3.58e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—HRAS—colon cancer	2.13e-06	3.57e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—AKT1—colon cancer	2.13e-06	3.57e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—EP300—colon cancer	2.08e-06	3.49e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—HRAS—colon cancer	2.03e-06	3.41e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—SRC—colon cancer	2.02e-06	3.39e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PTGS2—colon cancer	2e-06	3.35e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—VEGFA—colon cancer	1.97e-06	3.3e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PPARG—colon cancer	1.97e-06	3.3e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.95e-06	3.27e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NRAS—colon cancer	1.95e-06	3.26e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—AKT1—colon cancer	1.94e-06	3.26e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PPARG—colon cancer	1.92e-06	3.22e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PTGS2—colon cancer	1.89e-06	3.17e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—AKT1—colon cancer	1.88e-06	3.15e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MYC—colon cancer	1.81e-06	3.04e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PPARG—colon cancer	1.81e-06	3.03e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TGFB1—colon cancer	1.81e-06	3.03e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—AKT1—colon cancer	1.79e-06	3.01e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PPARG—colon cancer	1.79e-06	3.01e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PTGS2—colon cancer	1.72e-06	2.89e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PIK3CA—colon cancer	1.72e-06	2.88e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ABCB1—colon cancer	1.7e-06	2.85e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—KRAS—colon cancer	1.67e-06	2.81e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—TYMS—colon cancer	1.67e-06	2.8e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—EP300—colon cancer	1.66e-06	2.79e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—EP300—colon cancer	1.57e-06	2.64e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PTGS2—colon cancer	1.55e-06	2.59e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PIK3CA—colon cancer	1.54e-06	2.58e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PTGS2—colon cancer	1.51e-06	2.53e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TP53—colon cancer	1.49e-06	2.5e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—EP300—colon cancer	1.43e-06	2.4e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—HRAS—colon cancer	1.42e-06	2.39e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PTGS2—colon cancer	1.42e-06	2.38e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PTGS2—colon cancer	1.41e-06	2.36e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—AKT1—colon cancer	1.4e-06	2.35e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—EP300—colon cancer	1.29e-06	2.16e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—AKT1—colon cancer	1.26e-06	2.11e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—EP300—colon cancer	1.26e-06	2.1e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CA—colon cancer	1.23e-06	2.06e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—EP300—colon cancer	1.18e-06	1.98e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PPARG—colon cancer	1.18e-06	1.98e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—EP300—colon cancer	1.17e-06	1.97e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CA—colon cancer	1.16e-06	1.95e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CA—colon cancer	1.06e-06	1.78e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—AKT1—colon cancer	1.01e-06	1.69e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CA—colon cancer	9.52e-07	1.6e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—AKT1—colon cancer	9.5e-07	1.59e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PTGS2—colon cancer	9.3e-07	1.56e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CA—colon cancer	9.29e-07	1.56e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CA—colon cancer	8.75e-07	1.47e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CA—colon cancer	8.68e-07	1.45e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—AKT1—colon cancer	8.66e-07	1.45e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—AKT1—colon cancer	7.77e-07	1.3e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—EP300—colon cancer	7.74e-07	1.3e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—AKT1—colon cancer	7.59e-07	1.27e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—AKT1—colon cancer	7.15e-07	1.2e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—AKT1—colon cancer	7.09e-07	1.19e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CA—colon cancer	5.72e-07	9.59e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—AKT1—colon cancer	4.67e-07	7.84e-06	CbGpPWpGaD
